ESMO 2021 | PSMAddition: 177Lu-PSMA-617 plus SOC vs. SOC alone in metastatic hormone-sensitive prostate cancer

Name: PSMAddition: 177Lu-PSMA-617 plus SOC vs. SOC alone in metastatic hormone-sensitive prostate cancer
Uploaded: 2021-09-17T00:00:00Z
Duration: 5 min 6 s

Scott Tagawa • 17 Sep 2021

ESMO 2021

Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617

PSMAddition VISION

Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medicine, New York City, NY, provides an overview of an ongoing Phase III study named PSMAddition (NCT04720157) which aims to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus standard of care alone in patients with metastatic hormone-sensitive prostate cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Disclosures

Dr Tagawa reports research support (to Weill Cornell since 2007) for Sanofi, Medivation, Astellas, Janssen, Amgen, Progenics, Dendreon, Lilly, Genentech, Newlink, BMS, Inovio, AstraZeneca, Immunomedics, Aveo, Rexahn, Atlab, Boehringer Ingelheim, Millennium, Bayer, Merck, Abbvie, Karyopharm, Endocyte, Clovis, Seattle Genetics, Novartis, Gilead, POINT Biopharma.

Dr Tagawa reports paid consultancy (since 2007) for Sanofi, Medivation/Astellas, Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, Abbvie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer, AAA/Novartis, Clarity, Genomic Health, POINT Biopharma, Blue Earth Diagnostics, AIkido Pharma, Telix Pharma, Convergent Therapeutics.

Dr Tagawa reports unpaid consultancy for Atlab Pharma, Phosplatin Therapeutics, Amgen, Ambrx